BioLineRx Ltd. (NASDAQ:BLRX) – Analysts at Oppenheimer Holdings dropped their FY2021 EPS estimates for shares of BioLineRx in a report released on Tuesday. Oppenheimer Holdings analyst M. Breidenbach now expects that the biotechnology company will post earnings per share of $0.02 for the year, down from their prior estimate of $0.06. Oppenheimer Holdings currently has a “Buy” rating and a $3.00 target price on the stock.
Several other research analysts have also recently weighed in on the company. HC Wainwright set a $4.00 price objective on BioLineRx and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Roth Capital began coverage on BioLineRx in a research note on Thursday, August 3rd. They issued a “buy” rating and a $3.00 target price on the stock. Zacks Investment Research upgraded BioLineRx from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research note on Tuesday, October 3rd. Finally, ValuEngine lowered BioLineRx from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $2.88.
TRADEMARK VIOLATION WARNING: “FY2021 Earnings Forecast for BioLineRx Ltd. Issued By Oppenheimer Holdings (BLRX)” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.com-unik.info/2017/11/23/fy2021-earnings-forecast-for-biolinerx-ltd-issued-by-oppenheimer-holdings-blrx.html.
An institutional investor recently raised its position in BioLineRx stock. KCG Holdings Inc. raised its position in BioLineRx Ltd. (NASDAQ:BLRX) by 715.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 175,156 shares of the biotechnology company’s stock after buying an additional 153,687 shares during the quarter. KCG Holdings Inc. owned about 0.28% of BioLineRx worth $168,000 at the end of the most recent reporting period. Institutional investors own 32.59% of the company’s stock.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
What are top analysts saying about BioLineRx Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioLineRx Ltd. and related companies.